Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Wednesday its net profit rose 21% to 100 billion Danish kroner ($13.9 billion) last year.
Europe's most valuable company also reported a 25% increase in sales, reaching 290.4 billion Danish kroner.